Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Pharmaseek Financial Services

Neither a doctor nor a teaching hospital

Research payments

$4,423,818

355 payments

Through program year 2025, Pharmaseek Financial Services is reported as receiving $4,423,818 in research payments, across 355 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $18,394 2
2024 Research $24,572 2
2023 Research $115,184 3
2022 Research $159,100 6
2021 Research $355,905 49
2020 Research $1,118,120 127
2019 Research $2,632,543 166

Breakdown

Who paid Research payments · program years 2019–2025
  1. Allergan Inc. $1,451,524 98 payments
  2. CSL Behring $900,721 105 payments
  3. Eli Lilly and Company $889,140 21 payments
  4. Genentech, Inc. $602,167 53 payments
  5. Ironwood Pharmaceuticals, Inc $423,702 42 payments
  6. Shire North American Group Inc $55,472 12 payments
  7. Novartis Pharmaceuticals Corporation $46,181 5 payments
  8. GlaxoSmithKline, LLC. $31,260 10 payments
  9. Puma Biotechnology, Inc. $14,538 2 payments
  10. Neurocrine Biosciences, Inc. $4,200 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. AURORA A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis $881,904 11 payments
  2. Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II $602,559 61 payments
  3. Phase III Study of Balovaptan in Adults With Asd $498,458 29 payments
  4. AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis $455,423 53 payments
  5. Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo After An Intensive Lifestyle Program in Participants Without Type 2 Diabetes Who Have Obesity Or Are Overweight With Weight-Related Comorbidities: A Randomized, Double Blind, Placebo-Controlled Trial (Surmount-3) $342,327 2 payments
  6. Phase 1, Open-Label, Parallel-Cohort, Single-Dose Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of Loxo-292 $316,215 5 payments
  7. A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome $298,163 44 payments
  8. C3718-301 $190,558 6 payments
  9. C3718-302 $155,705 10 payments
  10. AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis $114,197 34 payments
What the money was spent on Research payments · program years 2019–2025
  1. Other $1,635 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record